Due to COVID-19 we are now offering TeleHealth Office Visits via video or phone call. Learn More >
We have prepared for the Coronavirus (COVID-19). We have updated policies to protect our patients and staff. Learn more.

Radioactive Seed Implants Can Treat Prostate Cancer Effectively in Texas

Brachytherapy is a treatment for prostate cancer that involves the implantation of tiny radioactive seeds at the tumor location. Low dose rate brachytherapy has offered excellent outcomes in patients with prostate cancer.

Low dose rate brachytherapy is when a doctor implants radioactive seeds inside the prostate gland. The procedure is guided by an ultrasound. The number of seeds and the targeted location is determined by a developed treatment plan tailored for every patient. Implanted seeds may range from 40 to 100.

Once implanted, the radioactive seeds will remain in the body permanently. After some months, the seeds will become biologically inert. This radiation causes no harm to the surrounding tissues.

It was concluded in a study that low dose rate brachytherapy offers excellent disease-specific survival rates in patients with localized prostate cancer. It is an effective alternative to radical prostatectomy as it is associated with high rates (17 years) of cancer-specific and distant metastases free survival rates.

In the study;

  • Men with localized prostate cancer were put on definitive low-dose-rate brachytherapy and followed up for a median of 12.5 years. It was found that 88.6% of the patients were alive, while 1.5% died from prostate cancer. 13.9% of the patients experienced biochemical failure, while 2.3% were found to have developed distant metastases.
  • The overall 17-year survival rates for biochemical failure-free survival, prostate cancer-specific survival, distant metastases-free survival, and overall survival were 79%, 97%, 97%, and 72%, respectively.
  • Of those who experienced biochemical failure, 18% of them went on for more than 10 years after their brachytherapy treatment.
  • During multivariate analysis, stage T3a-T3b disease, PSA levels above 20ng/ml, and intermediate and high-risk disease predicted worse biochemical failure-free survival. Those older than 70 years at the time of diagnosis and stage T3a-T3b disease predicted worse overall survival.

Overall, low dose rate brachytherapy is a non-invasive procedure that takes about 90 minutes. Most patients who undergo the treatment go home on the same day. The results from studies show that low dose rate brachytherapy can treat prostate cancer with excellent outcomes.

More Choice Cancer Care Centers